Fujifilm India enhances disease management and prognosis with advanced screening solutions


Accurate and early clinical assessment of the SARS-CoV-2 is vital and Fujifilm India informed that with it’s advanced Dri Chemistry solutions can aid doctors in a quick analysis of LDH and CRP testing of patients in just six minutes.

Fujifilm India Private Limited, a pioneer in imaging and healthcare technologies, in line with its commitment to provide aid for the unprecedented crisis, has been strengthening its pledge to contribute to healthcare experts with the help of its progressive Dri Chemistry solutions is helping in conducting the prognosis within just six minutes.

Recent research suggests that relatively high levels of LDH alone seem to play a crucial role in distinguishing the vast majority of cases that require immediate medical attention. This finding is consistent with current medical knowledge that high LDH levels are associated with tissue breakdown occurring in various diseases, including pulmonary disorders such as pneumonia. The use of the biomarkers suggests a simple and operable decision rule to quickly predict patients at the highest risk, allowing them to be prioritized and potentially reducing the mortality rate.

Also read: Fujifilm — Making India Future Ready in Diagnostic World

With Fujifilm’s dry chemistry analyzer, healthcare professionals can perform multiple test parameters of Clinical Chemistry. It has a built-in auto-pipetting system, requires no calibration and no water, providing easy preparation and maintenance. The new FUJI DRI-CHEM NX500i and NX700i deliver results using a simple 3-step procedure. With its quick, easy operation and compactness, “Real Time and Borderless” Clinical Chemistry has now been made possible.

“As India battles the highest number of coronavirus cases each day, Fujifilm is committed to support the healthcare professionals with our advanced technological solutions. Our cutting-edge Dri Chem technological solutions can help doctors decide how actively they need to handle patients, track their discharge and other clinical decisions. At Fujifilm, we believe it’s time for all of us to come together and protect humanity by acting responsibly and by doing what we can do to prevent further spread of COVID-19,” said Chander Shekhar Sibal, Senior Vice President, Fujifilm India.

Fujifilm’s clinical chemistry solutions deliver fine chemical technology which is Japanese patented technology for manufacturing of Dri Chemistry Slides. The slides ensure ease of work and no trained technicians are required to use the medical solutions. Further with plug and play equipment, the NX500i can run upto 128 tests per hour and the NX700i can run upto 190 tests per hour respectively.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top